Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 212561
Company: YICHANG HUMANWELL

Products on ANDA 212561

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
POTASSIUM CHLORIDE	POTASSIUM CHLORIDE	10MEQ	TABLET, EXTENDED RELEASE;ORAL	Prescription	AB3	No	No
POTASSIUM CHLORIDE	POTASSIUM CHLORIDE	20MEQ	TABLET, EXTENDED RELEASE;ORAL	Prescription	AB3	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 212561

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
09/30/2019	ORIG-1	Approval		STANDARD		Label is not available on this site.

Therapeutic Equivalents for ANDA 212561

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL; 10MEQ
TE Code = AB3

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
POTASSIUM CHLORIDE	POTASSIUM CHLORIDE	10MEQ	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB3	215725	RUBICON
POTASSIUM CHLORIDE	POTASSIUM CHLORIDE	10MEQ	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB3	209688	TWI PHARMS
POTASSIUM CHLORIDE	POTASSIUM CHLORIDE	10MEQ	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB3	212561	YICHANG HUMANWELL

TABLET, EXTENDED RELEASE;ORAL; 20MEQ
TE Code = AB3

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
POTASSIUM CHLORIDE	POTASSIUM CHLORIDE	20MEQ	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB3	215725	RUBICON
POTASSIUM CHLORIDE	POTASSIUM CHLORIDE	20MEQ	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB3	209688	TWI PHARMS
POTASSIUM CHLORIDE	POTASSIUM CHLORIDE	20MEQ	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB3	212561	YICHANG HUMANWELL